Multimodality imaging in thoracic aortic diseases: a clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases

Artur Evangelista*, Marta Sitges, Guillaume Jondeau, Robin Nijveldt, Mauro Pepi, Hug Cuellar, Gianluca Pontone, Eduardo Bossone, Maarten Groenink, Marc R. Dweck, Jolien W. Roos-Hesselink, L. Mazzolai, Roland van Kimmenade, Victor Aboyans, Jose Rodríguez-Palomares

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)

Abstract

Imaging techniques play a pivotal role in the diagnosis, follow-up, and management of aortic diseases. Multimodality imaging provides complementary and essential information for this evaluation. Echocardiography, computed tomography, cardiovascular magnetic resonance, and nuclear imaging each have strengths and limitations in the assessment of the aorta. This consensus document aims to review the contribution, methodology, and indications of each technique for an adequate management of patients with thoracic aortic diseases. The abdominal aorta will be addressed elsewhere. While this document is exclusively focused on imaging, it is of most importance to highlight that regular imaging follow-up in patients with a diseased aorta is also an opportunity to check the patient's cardiovascular risk factors and particularly blood pressure control.

Original languageEnglish
Pages (from-to)e65-e85
JournalEuropean heart journal. Cardiovascular Imaging
Volume24
Issue number5
DOIs
Publication statusPublished - 1 May 2023

Bibliographical note

Funding Information:
Conflict of interest: A.E.: Nothing to be declared. M.S.: Speaker and consultancy fees from Abbott (Heart Valve Disease), Edwards Lifesciences (Heart Valve Disease), Medtronic (Heart Valve Disease). Research funding from Bristol Myers Squibb (Atrial Fibrillation), Menarini (Education on Cardiovascular Diseases), Novartis (Heart Failure), Rovi (Heart Failure), Amgen (Hypercholesterolemia), Merck Sharp & Dohme (Hypercholesterolemia). V.A.: Speaker and consultancy fees from Bayer Healthcare (Antithrombotic therapies), Novo-Nordisk (Diabetes), Astrazeneca (Diabetes), Boehringer Ingelheim (Diabetes). E.B.: Nothing to be declared. H.C.: Nothing to be declared. M.R.D.: Speaker and consultancy fees from Beren, Silence Therapeutics (aortic stenosis), Jupiter Bioventures (coronary atherosclerosis), Novartis (aortic stenosis, coronary atherosclerosis), Pfizer (cardiac amyloidosis).

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.

Fingerprint

Dive into the research topics of 'Multimodality imaging in thoracic aortic diseases: a clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases'. Together they form a unique fingerprint.

Cite this